Figure 2 Simplified EULAR and GRAPPA

Slides:

Advertisements

Similar presentations

GRAPPA Guidelines for PsA: Considerations

Advertisements

Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska MD,

Nat. Rev. Rheumatol. doi: /nrrheum

Psoriatic Arthritis.

Summary of TB cases across indications and trial periods

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Enthesitis versus synovitis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Microanatomical changes in enthesitis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 3 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Biotherapeutics.

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Updated 2016 PsA Core Domain Set.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Percentage of patients achieving EULAR response

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 Principles for the diagnosis and management of osteoarthritis

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Nat. Rev. Cardiol. doi: /nrcardio

Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.

Nat. Rev. Rheumatol. doi: /nrrheum

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Associations between the ‘% of patients that ever used a bDMARD’ and the ‘composite score clinical criteria’, ‘composite score access to medication’ and.

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

Multivariable model of adjusted

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

Psoriatic Arthritis.

Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Figure 2 Simplified EULAR and GRAPPA treatment algorithms for predominant entheseal psoriatic arthritis5,6 Figure 2 | Simplified EULAR and GRAPPA treatment algorithms for predominant entheseal psoriatic arthritis5,6. The order of drug use proposed for patients with psoriatic arthritis (PsA) and predominant entheseal involvement, with a step-up approach (indicated by staggered boxes) in case of inefficacy or toxicity. *Conditional recommendation in the GRAPPA guidelines for drugs without current regulatory approval or where recommendations are based on abstract data only. bDMARD, biologic DMARD; EULAR, European League Against Rheumatism; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; PDE4, phosphodiesterase 4. Gossec, L. et al. (2016) Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.183